Sanofi (SNYNF) Total Liabilities (2009 - 2025)
Sanofi (SNYNF) posted Total Liabilities of $149.9 billion for Q1 2026, up 972.83% sequentially from $14.0 billion in Q4 2025, and up 8.04% YoY from $138.7 billion in Q1 2025.
Sanofi (SNYNF) Total Liabilities (2009 - 2025) Analysis & Trends
Sanofi (SNYNF) has 18 years of Total Liabilities data on file, last reported at $149.9 billion in Q1 2026.
- Quarterly Total Liabilities rose 8.04% year-over-year to $149.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $502.3 billion (up 151.3% YoY) and the FY2025 annual result came in at $14.0 billion, down 76.35% from the prior year.
- Total Liabilities rose to $149.9 billion in Q1 2026 per SNYNF's latest filing, from $14.0 billion in the prior quarter.
- The five-year high for Total Liabilities was $151.7 billion in Q3 2025, with the low at $14.0 billion in Q4 2025.
- Average Total Liabilities over 5 years is $77.9 billion, with a median of $59.1 billion recorded in 2024.
- Year-over-year, Total Liabilities tumbled 76.35% in 2025 and gained 8.04% in 2026.
- Sanofi's Total Liabilities stood at $53.0 billion in 2022, then advanced by 6.45% to $56.4 billion in 2023, then climbed by 4.75% to $59.1 billion in 2024, then plunged by 76.35% to $14.0 billion in 2025, then surged by 972.83% to $149.9 billion in 2026.
- Business Quant data shows SNYNF's Total Liabilities at $149.9 billion in Q1 2026, $14.0 billion in Q4 2025, and $151.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 85.38 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.71 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 143.12 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -66.63 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 82.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.97 Bn |
| Jun 30, 2025 | 61.90 Bn |
| Dec 31, 2024 | 59.08 Bn |
| Jun 30, 2024 | 61.12 Bn |
| Dec 31, 2023 | 56.41 Bn |
| Jun 30, 2023 | 57.07 Bn |
| Dec 31, 2022 | 52.99 Bn |
| Jun 30, 2022 | 53.91 Bn |
| Dec 31, 2021 | 58.98 Bn |
| Jun 30, 2021 | 58.96 Bn |
| Dec 31, 2020 | -73.33 Bn |
| Jun 30, 2020 | 57.64 Bn |
| Dec 31, 2019 | 3.09 Bn |
| Jun 30, 2019 | 60.71 Bn |
| Dec 31, 2018 | 2.32 Bn |
| Sep 30, 2018 | 458.27 Mn |
| Jun 30, 2018 | 134.59 Bn |
| Dec 31, 2017 | 2.74 Bn |
| Jun 30, 2017 | 48.47 Bn |
| Dec 31, 2016 | 2.62 Bn |